Tag: ATB-352

August 29, 2018

Antibe Therapeutics Reports Full Phase 2B ATB-346 Trial Results

The trial, which originally finished in March 2018, shows that ATB-346 met the primary endpoint of reduced ulceration rate.
May 22, 2018

Antibe Therapeutics Looking for More Licensing Deals

Antibe Therapeutics is trying to change the game of non-steroidal anti-inflammatory drugs (NSAID)—the “largest category of drugs globally,” CEO Dan...